Paper Details

  1. Home
  2. Paper Details

Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.

Author: BijlsmaJohannes W J, JacobsWilco, den BroederAlfons A, van HerwaardenNoortje, van VollenhovenRonald F, van den BemtBart J F, van der MaasAatke

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

While anti-TNF medications are effective for rheumatoid arthritis (RA), they can have side effects and are expensive. This study explores the effectiveness of reducing the dose of these medications (down-titration) compared to continuing the standard dose to determine if lower doses can still provide benefits while reducing potential side effects and costs.
Paper Details　
Original Abstract of the Article :
Anti-tumor necrosis factor (TNF) agents are effective in treating patients with rheumatoid arthritis (RA), but they are associated with (dose-dependent) adverse effects and high costs. To prevent overtreatment, several trials have assessed the effectiveness of down-titration compared with continuati...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/14651858.CD010455.pub2

データ提供：米国国立医学図書館（NLM）

Down-Titration of TNF-Blocking Agents: Finding the Right Balance in the Desert of Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory disease that can leave individuals feeling trapped in a desert of pain and discomfort. This study explores the effectiveness of down-titration strategies for tumor necrosis factor (TNF)-blocking agents, a class of medications commonly used to treat RA. The researchers investigated whether reducing the dose of TNF-blocking agents in patients with low disease activity could be a viable option for managing RA while minimizing potential side effects and costs.

Down-Titration: A Path to Sustainability in the Desert of RA

The study's findings suggest that down-titration strategies for TNF-blocking agents may offer a sustainable approach to managing RA. The researchers found that down-titration was effective in maintaining low disease activity in many patients, demonstrating that reducing the dose of these medications can be a viable option without compromising treatment effectiveness. This discovery is like finding a sustainable source of water in the desert, allowing individuals to manage their RA without the burden of high doses and potential side effects.

Navigating the Desert of RA: Finding the Right Treatment Path

The study's findings highlight the potential benefits of down-titration strategies for TNF-blocking agents in RA management. However, it's important to consult with a qualified rheumatologist to discuss your individual needs and determine the most appropriate treatment approach. They will consider your disease activity, medical history, and personal preferences to create a personalized plan that maximizes effectiveness while minimizing risks. Just as a desert traveler needs to adapt to the changing landscape, managing RA requires a collaborative approach with your healthcare provider and ongoing monitoring to ensure optimal outcomes.

Dr. Camel's Conclusion

Down-titration of TNF-blocking agents shows promise in RA management, offering a potential path to sustained control with reduced side effects and costs. However, personalized treatment plans and close collaboration with a rheumatologist are essential.

Date :
  1. Date Completed 2015-10-02
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

25264908

DOI: Digital Object Identifier

10.1002/14651858.CD010455.pub2

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.